Clinical trials in Brussels – page 14

In Bruxelles, several trials focus on neoplasms, especially breast cancer, colorectal cancer, lung cancer, glioblastoma, soft tissue sarcoma, and other advanced solid tumors. These studies are designed to test new treatment combinations, improve survival outcomes, and refine more personalized care for people with difficult-to-treat cancers.

• ER-positive, HER2-negative breast cancer and related high-risk disease
• EGFR-mutated non-small cell lung cancer and metastatic lung disease
• Glioblastoma and other advanced brain tumors
• Colon cancer, rectal cancer with liver metastasis, and broader advanced solid tumors

Much of this research aims to evaluate whether new therapeutic approaches can better control tumor growth and extend disease-free or overall survival.

Clinical trial activity in Bruxelles also includes nervous system diseases, with a strong focus on acute ischemic stroke and intracerebral haemorrhage. The main goal is to improve recovery after stroke and assess safer, more effective treatment strategies in urgent care settings.

• Acute ischemic stroke with incomplete reperfusion
• Stroke in patients with recent direct oral anticoagulant use
• Intracerebral haemorrhage and prevention of later vascular events

These studies are centered on improving functional outcomes, supporting better reperfusion, and understanding how to optimize care after a stroke.

Research in respiratory tract diseases is active, particularly for pneumonia and severe infections requiring hospital or intensive care support. The trials are examining ways to reduce complications, improve recovery, and measure whether new add-on treatments can make standard care more effective.

• Severe community-acquired pneumonia
• Hospital-acquired pneumonia
• Severe pneumonia in critically ill patients

This area includes efforts to test supportive treatments that may help improve survival and shorten the time patients spend in hospital.

Trials in cardiovascular diseases are studying conditions such as cardiogenic shock and other severe acute cardiac or circulatory emergencies. The research is focused on evaluating treatment effectiveness and safety in life-threatening situations where rapid decision-making is essential.

• Cardiogenic shock linked to acute coronary syndrome
• Cardiogenic shock of septic origin
• Cardiogenic shock due to acute decompensated heart failure

These studies aim to provide reliable evidence on outcomes such as mortality and time to hospital discharge.

A distinct group of studies addresses immune system diseases and virus diseases, with work on psoriasis, human papillomavirus, Epstein-Barr virus, and non genital warts. The research is designed to assess symptom improvement, infection clearance, and the longer-term safety of treatment options.

• Moderate to severe plaque psoriasis
• HPV infection and genital wart disease
• Epstein-Barr virus infection
• Non genital warts

These trials reflect a mix of symptom-focused and infection-focused research in common yet persistent conditions.

Bruxelles is also hosting studies in bacterial infections and mycoses as well as chronic viral disease, including HIV. The emphasis is on improving clinical outcomes, supporting recovery, and testing therapies that may better control infection-related complications.

• HIV in patients with suppressed viral load
• Hospital-acquired and severe respiratory infections
• Viral and skin infections associated with HPV and EBV

This area combines prevention, symptom control, and treatment-response research across several infection types.

Several trials are specifically focused on breast cancer, including early-stage, locally advanced, and metastatic disease. The research explores more individualized treatment strategies, including approaches guided by tumor biology and relapse risk.

• ER-positive, HER2-negative breast carcinoma
• Premenopausal high-risk HR-positive breast cancer
• High-risk relapse after initial breast cancer treatment

These studies are intended to help match treatment intensity more closely to a patient’s risk profile and tumor characteristics.

Research in digestive system diseases includes studies of colon cancer and rectal cancer, with special attention to older adults and patients with higher recurrence risk. The main goal is to compare treatment strategies that may improve long-term cancer control.

• Stage III colon cancer
• Upper rectal cancer
• Colon and rectal cancer with liver metastasis

This work explores how postoperative treatment choices can support better relapse-free survival and overall disease management.

Another research stream addresses longer-term treatment safety in immune system diseases, especially for chronic inflammatory conditions. In the city of Bruxelles, investigators are comparing whether newer therapies can maintain effectiveness while reducing health risks over time.

• Moderate-to-severe plaque psoriasis
• Cardiovascular safety in long-term treatment use
• Comparative treatment safety in chronic inflammatory disease

These trials are aimed at supporting safer long-term management for people living with chronic conditions.

Some trials cannot be neatly placed into a single therapeutic category, but they still contribute to the broader oncology and clinical research landscape. These studies often focus on evaluating new treatment options for patients with limited standard choices.

• Participants with advanced solid tumors
• Metastatic or advanced cancer populations
• Recurrent glioblastoma and other hard-to-treat disease settings

The common aim is to test whether emerging therapies can offer meaningful benefit where current options remain limited.